Amyotrophic Lateral Sclerosis
Research Highlights/News
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2007
» Look for consumer stories click here
2023
News:
- USC Stem Cell-led studies point the way to broadly effective treatments for ALS (external link)
Keck School of Medicine of USC, March 6, 2023
2022
Press Releases:
- Department of Defense Amyotrophic Lateral Sclerosis Research Program Anticipated Funding Opportunities for Fiscal Year 2023 (FY23)
December 12, 2022
Research Highlights:
- A Combined Cell and Gene Therapy Approach for Preserving Motor Neuron Function in ALS
- UPDATE: ALS Treatment, Tegoprubart, Advancing Through Clinical Trials
- A New Compound to Prevent Motor Neuron Toxicity in ALS Enters Clinical Trial
- In Vivo Imaging and Novel Therapeutic Approaches in ALS
- A Challenge Best Tackled Together – Bridging the ALS Therapeutic Gap with Industry Partners
News:
- Digital Speech Biomarkers Show Promise in Recording Speech Function, Dysarthria in ALS (external link)
NeurologyLive, November 15, 2022 - Neurodegenerative disease can progress in newly identified patterns (external link)
MIT News, October 26, 2022 - Eledon Announces Phase 2a Trial Results of Tegoprubart (AT-1501) - a Drug Invented at ALS TDI (external link)
PR.com, June 17, 2022 - Funding Supports Continued Development of M102 in Amyotrophic Lateral Sclerosis (external link)
Aclipse Therapeutics, April 29, 2022
2021
Press Releases:
- Department of Defense Amyotrophic Lateral Sclerosis Research Program Anticipated Funding Opportunities for Fiscal Year 2022 (FY22)
December 8, 2021
Research Highlights:
News:
- AcuraStem's Development Candidate AS-202 Demonstrates Excellent Safety and Potency in Preclinical Models Representing Diverse Forms of ALS (external link)
AcuraStem, December 16, 2021 - AcuraStem Awarded $1M DOD Grant to Advance AS-202 Drug Development Candidate for ALS (external link)
AcuraStem, May 27, 2021
2020
Press Releases:
- Department of Defense Amyotrophic Lateral Sclerosis Research Program Anticipated Funding Opportunities for Fiscal Year 2021 (FY21)
December 22, 2020
Research Highlights:
News:
- New study shows common diabetes drug improves symptoms in genetic form of ALS in mice (external link)
University of Florida Health, July 23 , 2020
2019
Press Releases:
-
Department of Defense Amyotrophic Lateral Sclerosis Research Program Funding Opportunities for Fiscal Year 2020 (FY20)
December 6, 2019 -
Department of Defense Amyotrophic Lateral Sclerosis Research Program Anticipated Funding Opportunities for Fiscal Year 2019 (FY19)
October 16, 2018
Research Highlights:
- ALS “Disease in a Dish” Creates Opportunities for Advanced Motor Neuron and Therapeutic Drug Screening
- Amyotrophic Lateral Sclerosis (ALS) Treatment, AT-1501, Enters Clinical Trial
2018
Press Releases:
-
Department of Defense Amyotrophic Lateral Sclerosis Research Program Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)
February 20, 2018
Research Highlights:
News:
- Genetic cause of ALS and frontotemporal dementia blocked by RNA-binding compound (external link)
Phys Org, December 31, 2018 - Treeway Announces Promising Data from Phase I Clinical Trial of Lead Program TW001 for ALS (external link)
Business Wire, June 1, 2018 - ALS Treatment Delays Disease and Extends Life in Rats (external link)
Cedars-Sinai, April 23, 2018
2017
Press Releases:
-
Department of Defense Amyotrophic Lateral Sclerosis Research Program Funding Opportunities for Fiscal Year 2017
January 23, 2017
News:
- Pimozide Identified as a Potential ALS Therapeutic (external link)
ALS Association, December 14, 2017 - Dr. John Ravits, ALSRP Programmatic Panel Member, Receives Sheila Essey Award for Research Contributions (external link)
ALS Association, March 31, 2017
2016
Press Releases:
-
Department of Defense Amyotrophic Lateral Sclerosis Research Program Funding Opportunities for Fiscal Year 2016
January 4, 2016
Research Highlights:
- Targeting miR-155 in Peripheral Monocytes for the Treatment of ALS
- The Petrucelli group creates mice that model the most common cause of ALS and FTD
- Development of Copper ATSM as a Therapeutic for SOD-Familial and Sporadic ALS
News:
-
New therapy halts progression of Lou Gehrig's disease in mice (external link)
Oregon State University, February 12, 2016
2015
Press Releases:
-
Department of Defense Amyotrophic Lateral Sclerosis Research Program Funding Opportunities for Fiscal Year 2015
February 23, 2015
News:
-
Nuclear transport problems linked to ALS and FTD ( (external link)
National Institutes of Health, November 6, 2015
2014
Research Highlights:
- Improving the Effective Bioavailability of ALS Therapeutics
- Designing Pharmacological Agents that Inhibit the Aggregation of SOD1 by Increasing the Net Negative Charge of the Protein
News:
-
Toxin from Brain Cell Triggers Neuron Loss in Human ALS Model (external link)
Columbia University Medical Center, February 21, 2014
2013
Press Releases:
-
Department of Defense Amyotrophic Lateral Sclerosis Research Program Anticipated Funding Opportunities for Fiscal Year 2013
April 11, 2013
2012
Research Highlights:
News:
-
Developing New Compounds to Treat ALS (external link)
The Scripps Research Institute, October 15, 2012
Video Highlights:
2011
Research Highlights:
- Inhibitors of TDP-43 Aggregation and Toxicity in ALS
- Preclinical Studies of Induced Pluripotent Stem Cell-Derived Astrocyte Transplantation in ALS
News:
-
The Chicago ALS Association Newsletter Highlights an ALSRP Consumer Reviewer
Published: February 9, 2011
2010
Press Releases:
-
Department of Defense Amyotrophic Lateral Sclerosis Research Program Funding Opportunities for Fiscal Year 2010
February 11, 2010
Research Highlights:
2009
Press Releases:
-
Department of Defense Amyotrophic Lateral Sclerosis Research Program Funding Opportunities for Fiscal Year 2009
March 27, 2009
Research Highlights:
2007
Press Releases:
Last updated Monday, March 6, 2023